Research programme: SSAO inhibitors and substrates - Biotie Therapies
Latest Information Update: 06 Dec 2013
At a glance
- Originator Biotie Therapies Corp.
- Mechanism of Action Amine oxidase (copper-containing) inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 26 Mar 2009 Preclinical trials in Diabetes mellitus in Finland (unspecified route)